GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aethlon Medical Inc (NAS:AEMD) » Definitions » ROIC %
中文

Aethlon Medical (Aethlon Medical) ROIC %

: -560.19% (As of Dec. 2023)
View and export this data going back to 1999. Start your Free Trial

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Aethlon Medical's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -560.19%.

As of today (2024-04-24), Aethlon Medical's WACC % is 15.39%. Aethlon Medical's ROIC % is -452.97% (calculated using TTM income statement data). Aethlon Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Aethlon Medical ROIC % Historical Data

The historical data trend for Aethlon Medical's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aethlon Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,026.35 -744.51 -1,547.25 -944.79 -538.54

Aethlon Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -337.58 -326.21 -499.80 -471.33 -560.19

Competitive Comparison

For the Medical Devices subindustry, Aethlon Medical's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aethlon Medical ROIC % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's ROIC % distribution charts can be found below:

* The bar in red indicates where Aethlon Medical's ROIC % falls into.



Aethlon Medical ROIC % Calculation

Aethlon Medical's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2023 is calculated as:

ROIC % (A: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2022 ) + Invested Capital (A: Mar. 2023 ))/ count )
=-11.899 * ( 1 - 0% )/( (1.732 + 2.687)/ 2 )
=-11.899/2.2095
=-538.54 %

where

Aethlon Medical's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-14.268 * ( 1 - 0% )/( (2.621 + 2.473)/ 2 )
=-14.268/2.547
=-560.19 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aethlon Medical  (NAS:AEMD) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Aethlon Medical's WACC % is 15.39%. Aethlon Medical's ROIC % is -452.97% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Aethlon Medical ROIC % Related Terms

Thank you for viewing the detailed overview of Aethlon Medical's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aethlon Medical (Aethlon Medical) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Executives
Nicolas Gikakis director 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO CA 92121
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Steven P Larosa officer: Chief Medical Officer 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA 92123
Chetan Shah director 9 GRACE HILL COURT, TITUSVILLE NJ 08560
Fisher Charles J Jr director C/O AETHLON MEDICAL, INC., 9635 GRANITE RIDGE DR., SUITE 100, SAN DIEGO CA 92123
Guy F. Cipriani director 1727 EAGLERIDGE DRIVE, BELLINGHAM WA 98226
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Rodell Timothy C Jr officer: Interim CEO 201 MIDLAND AVE, ASPEN CO 81611
Weiner Family Revocable Trust Ellen R. 10 percent owner 10645 N. TATUM BOULEVARD, SUITE 200-166, PHOENIX AZ 85028
Phillip A Ward director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Thomas V Wornham director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Rodney S Kenley director, officer: President 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
James B Frakes officer: Chief Financial Officer 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
Barry Franklyn S Jr director 1141 DELAWARE AVENUE #3N, BUFFALO NY 14209